• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Elevance Health Announces John Gallina to Retire as CFO

    8/8/23 6:45:00 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Mark Kaye named Executive Vice President, Chief Financial Officer

    Elevance Health (NYSE:ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company's executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition.

    Gallina's distinguished career in the finance and healthcare fields spans more than four decades with nearly 30 of those years at Elevance Health where he was appointed as CFO in 2016 leading all financial and actuarial functions for the company including procurement and corporate real estate. Prior to his role as CFO, Gallina served in several leadership roles at the company including Senior Vice President and Chief Financial Officer for the Commercial and Specialty Business Division; Senior Vice President, Chief Accounting Officer, and Chief Risk Officer; Senior Vice President, Internal Audit and Continuous Improvement; and Chief Financial Officer of Comprehensive Health Services.

    "On behalf of the entire Elevance Health team, I want to thank John for his contributions to our company over the last three decades. John has been a valued member of our organization who has successfully led our finance organization, navigated an ever-changing and dynamic healthcare landscape, and played an important role in our transformation to become a lifetime trusted health partner," said Gail K. Boudreaux, President and CEO. "John's commitment to improve the health of the people and communities we serve is a testament to his career at Elevance Health and the driving force behind his dedication to guide the company through its cultural transformation," added Boudreaux.

    Kaye joins Elevance Health from Moody's Corporation, where he served as Chief Financial Officer with responsibility for all global finance activities. Kaye is a seasoned C-Suite executive with deep financial, actuarial, and business experience known for both his leadership and passion in creating and instilling a culture of excellence, and his commitment to long-term sustainability and inclusion. Before joining Moody's in 2018, Kaye held a variety of leadership roles in strategic finance, financial planning and analysis, and large-scale project management, including at MassMutual Life Insurance Company and Voya Financial.

    "Mark is a well-respected leader with an extensive global finance background, who has significant experience in leveraging data-driven financial insight to support the execution of superior operational and strategic decisions, including growing and scaling businesses to drive success," said Boudreaux. "With an innovative and customer first mindset coupled with his passion for fostering a high- performance culture, Mark will be a tremendous asset as we work to deliver on our purpose to improve the health of humanity. I'm pleased to welcome Mark to the Elevance Health team."

    Kaye holds an MBA in Finance and a BSE in Statistics and Actuarial Science from The Wharton School of Business and the University of Pennsylvania and is a Fellow of the Society of Actuaries.

    About Elevance Health, Inc.

    Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health's companies serve approximately 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230807319229/en/

    Get the next $ELV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    5/30/2024$649.00Outperform
    Robert W. Baird
    3/6/2024$584.00Overweight
    Barclays
    More analyst ratings

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health upgraded by Argus with a new price target

      Argus upgraded Elevance Health from Hold to Buy and set a new price target of $450.00

      3/17/25 8:22:06 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Stephens with a new price target

      Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously

      1/22/25 7:37:04 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Peru Ramiro G was granted 601 shares, increasing direct ownership by 7% to 9,345 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:24 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    SEC Filings

    See more
    • Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/28/25 6:31:33 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/14/25 5:27:34 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevance Health Inc.

      SCHEDULE 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      5/7/25 10:07:38 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/24 10:02:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/23 12:37:59 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

      Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

      3/6/24 4:30:00 PM ET
      $ELV
      $PFMT
      Medical Specialities
      Health Care
      Other Consumer Services
      Consumer Discretionary

    $ELV
    Financials

    Live finance-specific insights

    See more
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care